Skip to main content

Table 1 Clinical characteristics of COVID-19 autopsy cohort

From: Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

 

Diabetic patients

(N = 37)

Non-diabetic patients

(N = 60)

P

Age, years

65.9 ± 10.9

69.3 ± 9.4

0.107

Male, n (%)

23 (62.2)

37 (61.7)

0.515

BMI, kg/m2

28.9 ± 6.4

26.2 ± 1.9

0.019

Duration symptoms, days

14.3 ± 1.9

15.1 ± 2.1

0.065

Duration Hospitalization, days

11.3 ± 1.1

9.7 ± 1.2

0.002

Dyslipidemia, n (%)

7 (15.2)

30 (23.7)

0.181

Hypertension, n (%)

23 (62.2)

36 (60.0)

0.502

Obesity, n (%)

15 (40.5)

20 (33.3)

0.307

Cardiovascular disease, n (%)

12 (32.4)

21 (35.0)

0.322

COPD, n (%)

22 (59.5)

34 (56.7)

0.478

Smoking, n (%)

8 (21.6)

12 (20.0)

0.522

Patients with SARS-COV-2 infected cardiomyocytes, n (%)

30 (81.1)

17 (28.3)

0.001

Patients with SARS-COV-2 infected endothelial cells, n (%)

10 (27.0)

22 (36.7)

0.225

Patients with SARS-COV-2 infected macrophages, n (%)

20 (54.1)

41 (68.3)

0.116

Covid-19 drug therapy

   

 Antiviral (%)

37 (100)

60 (100)

/

 Antibiotics (%)

32 (86.5)

51 (85)

0.396

 Chinidine (%)

30 (81.1)

50 (83.3)

0.512

 Glucocorticoids (%)

29 (78.4)

49 (81.7)

0.215

 Tocilizumab (%)

4 (10.8)

6 (10)

0.510

 Oxygen inhalation (%)

31 (83.8)

50 (83.3)

0.256

  1. Data are means ± SD or n (%)
  2. BMI body mass index, COPD chronic obstructive pulmonary disease, SARS-COV-2 severe acute respiratory syndrome coronavirus 2